A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

NCT00849329 | Completed Phase 1

• 1 other identifier: 109275
• Study Type: interventional
• Target: 12
• Locations: 3 countries
• Sites: 4

Brief Summary

This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.

Conditions

Neoplasms, Breast

Keywords

lapatinib (GW572016), subject, pharmacokinetic, esomeprazole, proton-pump inhibitor, drug interaction, Phase 1

Outcome Measures

Primary Outcomes (1)

• The area under the concentration versus time curve, minimum observed concentration, maximum observed concentration, time at which it occurs, and lag time in the appearance of measurable plasma concentrations of lapatinb

  Continue until disease progression or withdrawal consent

Secondary Outcomes (1)

• Safety and tolerability assessments including evaluation of adverse events and changes in laboratory values, and vital signs.

  Continue until disease progression or withdrawal consent

Study Arms (2)

Period 1

EXPERIMENTAL

1250mg lapatinib once daily in the morning

Drug: lapatinib

Period 2

EXPERIMENTAL

1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.

Drug: lapatinib plus esomeprazole

Interventions

lapatinib DRUG

1250mg lapatinib

Period 1

lapatinib plus esomeprazole DRUG

1250mg lapatinib plus esomeprazole 40mg

Period 2

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Metastatic, histologically confirmed breast cancer that overexpresses ErbB2 (3+ by IHC, FISH, or CISH positive).
• years to 65 years of age.
• Is male or female (of non childbearing potential or willing to use contraception as specified in the protocol).
• Is able to swallow and retain oral medication.
• ECOG performance status 0 to 2.
• Provided written informed consent.
• Adequate bone marrow function (as specified in the protocol).
• Calculated creatinine clearance (CrCl) greater than or equal to 50 ml/min based on Cockcroft and Gault.
• Total bilirubin less than or equal to 1.5 X upper limit of normal of institutional values.
• Alanine transaminase (ALT) less than or equal to 3 times the upper limit of the institutional values or less than or equal to 5 times ULN with documented liver metastases
• Has a left ventricular ejection fraction (LVEF) within the normal institutional range based on ECHO or MUGA.
• Life expectancy of greater than or equal to 12 weeks
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

You may not qualify if:

• Pregnant or lactating woman.
• Has malabsorption syndrome, a disease affecting gastrointestinal function, or resection of the stomach or small bowel.
• Has current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
• Has evidence of symptomatic or uncontrolled brain metastases or leptomeningeal disease. Subjects with brain metastases treated by surgery and/or radiotherapy are eligible if neurologically stable and do not require steroids or anticonvulsants.
• Is considered medically unfit for the study by the investigator.
• Has a known immediate or delayed benzimidazole hypersensitivity reaction or idiosyncrasy to drugs chemically related to the investigational product such as gefitinib \[Iressa\] and erlotinib \[Tarceva\].
• Has received treatment with any investigational drug in the previous four weeks. (with the exception of lapatinib).
• Has received chemotherapy, immunotherapy, biologic therapy or hormonal therapy for the treatment of cancer within the past 14 days, with the exception of mitomycin C which is restricted for the past six weeks, and lapatinib. Subjects receiving lapatinib prior to study entry are eligible to participate in the study.
• Is receiving any prohibited medication within the timeframe indicated on the prohibited medication list in the protocol.
• Has physiological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
• Has inadequate venous access for protocol-related blood draws.
• Clinically significant electrocardiogram abnormality.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.
• Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or kumquats, pummelos, exotic citrus fruit (i.e. star fruit, bitter melon), grapefruit hybrids or fruit juices from seven days prior to the first dose of study medication.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (4)

GSK Investigational Site

Greenville, South Carolina, 29605, United States

Location

GSK Investigational Site

Seoul, 135-710, South Korea

Location

GSK Investigational Site

Songpa-gu, Seoul, 138-736, South Korea

Location

GSK Investigational Site

Hospitalet de Llobregat (Barcelona), 08907, Spain

Location

Related Links

• Results for study 109275 can be found on the GSK Clinical Study Register.

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Lapatinib; Esomeprazole

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Quinazolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Omeprazole; 2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Benzimidazoles

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 12, 2009
• First Posted: February 23, 2009
• Study Start: March 10, 2009
• Primary Completion: November 24, 2009
• Study Completion: November 24, 2009
• Last Updated: November 14, 2017

Record last verified: 2017-11

Locations

ES (1); US (1); KR (2)